Nontargeted circulating tumor DNA (ctDNA) whole-genome sequencing is a novel strategy for genomic characterization of high-grade serous ovarian cancer. Changes in ctDNA levels are a sensitive indicator of disease burden with an average lead time of 6 months to clinical progression. This presents a unique opportunity to identify pathways driving progression as molecular vulnerabilities for clinical drug development.

See related article by Paracchini et al., p. 2549

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.